<?xml version="1.0" encoding="UTF-8"?>
<CustomField xmlns="http://soap.sforce.com/2006/04/metadata">
    <fullName>Diagnosis_Manual__c</fullName>
    <description>Diagnosis to be populated manually for create or update for SA requests</description>
    <externalId>false</externalId>
    <label>Diagnosis (Manual)</label>
    <required>false</required>
    <trackFeedHistory>false</trackFeedHistory>
    <trackHistory>false</trackHistory>
    <trackTrending>false</trackTrending>
    <type>Picklist</type>
    <valueSet>
        <controllingField>Drug_Manual__c</controllingField>
        <restricted>true</restricted>
        <valueSetDefinition>
            <sorted>false</sorted>
            <value>
                <fullName>Gastroesophageal reflux disease (GERD),</fullName>
                <default>false</default>
                <label>Gastroesophageal reflux disease (GERD)</label>
            </value>
            <value>
                <fullName>Reflux esophagitis</fullName>
                <default>false</default>
                <label>Reflux esophagitis</label>
            </value>
            <value>
                <fullName>Duodenal ulcer</fullName>
                <default>false</default>
                <label>Duodenal ulcer</label>
            </value>
            <value>
                <fullName>Gastric ulcer</fullName>
                <default>false</default>
                <label>Gastric ulcer</label>
            </value>
            <value>
                <fullName>Barrett&apos;s esophagus</fullName>
                <default>false</default>
                <label>Barrett&apos;s esophagus</label>
            </value>
            <value>
                <fullName>Zollinger-Ellison syndrome</fullName>
                <default>false</default>
                <label>Zollinger-Ellison syndrome</label>
            </value>
            <value>
                <fullName>Connective tissue disease (e.g., lupus, scleroderma, crest),</fullName>
                <default>false</default>
                <label>Connective tissue disease (e.g., lupus, scleroderma, crest)</label>
            </value>
            <value>
                <fullName>Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)</fullName>
                <default>false</default>
                <label>Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)</label>
            </value>
            <value>
                <fullName>Depression</fullName>
                <default>false</default>
                <label>Depression</label>
            </value>
            <value>
                <fullName>Treatment failure or intolerance to at least one other sulfonylurea drug (e.g., glyburide, tolbutamide) at adequate doses</fullName>
                <default>false</default>
                <label>Treatment failure or intolerance to at least one other sulfonylurea drug (e.g., glyburide, tolbutamide) at adequate doses</label>
            </value>
            <value>
                <fullName>Patient has experienced intractable cough on an Angiotensin Converting Enzyme Inhibitor (ACE-I). Full coverage will be provided for all First Line ARBs</fullName>
                <default>false</default>
                <label>Patient has experienced intractable cough on an Angiotensin Converting Enzyme Inhibitor (ACE-I). Full coverage will be provided for all First Line ARBs</label>
            </value>
            <value>
                <fullName>Patient has experienced angioedema on an Angiotensin Converting Enzyme Inhibitor (ACE-I). Full coverage will be provided for all First Line ARBs</fullName>
                <default>false</default>
                <label>Patient has experienced angioedema on an Angiotensin Converting Enzyme Inhibitor (ACE-I). Full coverage will be provided for all First Line ARBs</label>
            </value>
            <value>
                <fullName>Cough or angioedema AND patient is currently taking stable doses of telmisartan and amlodipine</fullName>
                <default>false</default>
                <label>Cough or angioedema AND patient is currently taking stable doses of telmisartan and amlodipine</label>
            </value>
            <value>
                <fullName>Patient has experienced intractable cough on an ACE-I OR has experienced angioedema on an ACE-I. Full coverage will be provided for all First Line ARBs.</fullName>
                <default>false</default>
                <label>Patient has experienced intractable cough on an ACE-I OR has experienced angioedema on an ACE-I. Full coverage will be provided for all First Line ARBs.</label>
            </value>
            <value>
                <fullName>Other</fullName>
                <default>false</default>
                <label>Other</label>
            </value>
            <value>
                <fullName>Cough</fullName>
                <default>false</default>
                <isActive>false</isActive>
                <label>Cough</label>
            </value>
        </valueSetDefinition>
        <valueSettings>
            <controllingFieldValue>Rabeprazole</controllingFieldValue>
            <controllingFieldValue>Pantoprazole Magnesium</controllingFieldValue>
            <valueName>Gastroesophageal reflux disease (GERD),</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Rabeprazole</controllingFieldValue>
            <controllingFieldValue>Pantoprazole Magnesium</controllingFieldValue>
            <valueName>Reflux esophagitis</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Rabeprazole</controllingFieldValue>
            <controllingFieldValue>Pantoprazole Magnesium</controllingFieldValue>
            <valueName>Duodenal ulcer</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Rabeprazole</controllingFieldValue>
            <controllingFieldValue>Pantoprazole Magnesium</controllingFieldValue>
            <valueName>Gastric ulcer</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Rabeprazole</controllingFieldValue>
            <controllingFieldValue>Pantoprazole Magnesium</controllingFieldValue>
            <valueName>Barrett&apos;s esophagus</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Rabeprazole</controllingFieldValue>
            <controllingFieldValue>Pantoprazole Magnesium</controllingFieldValue>
            <valueName>Zollinger-Ellison syndrome</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Rabeprazole</controllingFieldValue>
            <controllingFieldValue>Pantoprazole Magnesium</controllingFieldValue>
            <valueName>Connective tissue disease (e.g., lupus, scleroderma, crest),</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Rabeprazole</controllingFieldValue>
            <controllingFieldValue>Pantoprazole Magnesium</controllingFieldValue>
            <valueName>Eradication of helicobacter pylori, as part of triple therapy (maximum 14 day approval)</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Rabeprazole</controllingFieldValue>
            <controllingFieldValue>Pantoprazole Magnesium</controllingFieldValue>
            <controllingFieldValue>Bupropion</controllingFieldValue>
            <controllingFieldValue>Gliclazide</controllingFieldValue>
            <controllingFieldValue>Candesartan</controllingFieldValue>
            <controllingFieldValue>Losartan</controllingFieldValue>
            <controllingFieldValue>Telmisartan</controllingFieldValue>
            <controllingFieldValue>Valsartan</controllingFieldValue>
            <valueName>Other</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Bupropion</controllingFieldValue>
            <valueName>Depression</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Gliclazide</controllingFieldValue>
            <valueName>Treatment failure or intolerance to at least one other sulfonylurea drug (e.g., glyburide, tolbutamide) at adequate doses</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Candesartan</controllingFieldValue>
            <controllingFieldValue>Losartan</controllingFieldValue>
            <controllingFieldValue>Telmisartan</controllingFieldValue>
            <controllingFieldValue>Valsartan</controllingFieldValue>
            <valueName>Patient has experienced intractable cough on an Angiotensin Converting Enzyme Inhibitor (ACE-I). Full coverage will be provided for all First Line ARBs</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Candesartan</controllingFieldValue>
            <controllingFieldValue>Losartan</controllingFieldValue>
            <controllingFieldValue>Telmisartan</controllingFieldValue>
            <controllingFieldValue>Valsartan</controllingFieldValue>
            <valueName>Patient has experienced angioedema on an Angiotensin Converting Enzyme Inhibitor (ACE-I). Full coverage will be provided for all First Line ARBs</valueName>
        </valueSettings>
        <valueSettings>
            <controllingFieldValue>Candesartan</controllingFieldValue>
            <controllingFieldValue>Losartan</controllingFieldValue>
            <controllingFieldValue>Telmisartan</controllingFieldValue>
            <controllingFieldValue>Valsartan</controllingFieldValue>
            <valueName>Patient has experienced intractable cough on an ACE-I OR has experienced angioedema on an ACE-I. Full coverage will be provided for all First Line ARBs.</valueName>
        </valueSettings>
    </valueSet>
</CustomField>
